STAR - STRIDES PHARMA SCIENCE LIMITED Share Price

Management's outlook for Strides Pharma Science Limited is optimistic, focusing on three primary strategic priorities: profitability, geographical diversification, and balance sheet strength.

Key forward-looking points include:

1. Profitability: The company has successfully enhanced its gross margins, achieving 59.8% overall and over 60% in certain areas. The Earnings Per Share (EPS) reached Rs. 41.4, indicating a robust performance. Management aims to maintain margins in the 58%-60% range.

2. Geographical Diversification: Ex-U.S. markets have shown significant promise, contributing 47% of revenues and growing 20% year-on-year in Q3 FY'26. Management indicated a desire to mirror U.S. market performance within two years, with an ongoing reduction in revenue gaps between U.S. and Ex-U.S. markets, currently at Rs. 500 million.

3. Balance Sheet Strength: The debt/EBITDA ratio is at 1.59x, down from 1.9x the previous fiscal year. The net debt has decreased by approximately Rs. 170 crores (Rs. 1,696 million) on a constant currency basis, showing disciplined financial management.

4. U.S. Market Performance: U.S. revenues remained flat at $70 million. Management attributed this primarily to seasonal fluctuations and some product discontinuations aimed at maintaining profitability. The long-term target for the U.S. is set at $400 million by FY'28, relying on product relaunches and investment in complex markets.

5. Investment and Personnel: The company plans to allocate over $400 million towards IP purchases and R&D initiatives to support future growth. Additionally, Peter Hardwick has been appointed as CEO of North American Business to enhance execution and customer focus.

Overall, the management is focused on sustaining growth through strategic investments, enhancing profitability, and expanding in both U.S. and Ex-U.S. markets, showing confidence in the operational framework and future market developments.

Question 1: What is the contribution of the eight products that are discontinued?

Answer: From an overall perspective, the contribution was not materially significant on an annual basis. While these discontinuations are part of our strategy focused on maintaining profitability, the overall impact on our financials is limited.

Question 2: What is the reason for lower or degrowth in the US business on a quarter-on-quarter or year-on-year basis?

Answer: Profitability remains our top priority. This quarter's muted growth in the U.S. was influenced mainly by a delayed flu season and the discontinuation of products that did not meet our profitability standards. We anticipate future growth as we continue to launch new products and improve market conditions.

Question 3: What is the sustainable gross margin?

Answer: We project our sustainable gross margin to range between 58% and 60%. While the current margin is around 61% due to favorable business mix, we aim to consistently operate around that higher end of this range over time, without guaranteeing it for every quarter.

Question 4: What is our debt in dollar terms and the increase in debt due to rupee depreciation?

Answer: Our total debt is roughly about $160 million. The increase in debt resulting from rupee depreciation is already reflected in our financial statements. We follow standardized accounting practice and ensure our financials accurately represent our position.

Question 5: Where do you expect the next leg of growth to come from?

Answer: Looking at a two-year outlook, we aim for $400 million in revenue from the U.S. market, and parallel growth in Ex-U.S. markets. We have identified several dormant products and are investing in R&D programs that should yield significant growth moving forward.

Question 6: Can we expect to see consistent growth in ORM?

Answer: Yes, we believe that the groundwork laid in the past two years will lead to sustainable growth in ORM. The regulatory pathways and partnerships we have established should contribute positively, allowing us to differentiate in the market going forward.

Question 7: How does competition affect growth in the U.S. market?

Answer: Competition is always present, and while we cannot predict specific outcomes, we're prepared to respond to challenges. Our focus remains on maintaining a diversified and balanced portfolio to mitigate the impact of competitive pressures on our growth trajectory.

Question 8: What is the expected cash-to-cash cycle?

Answer: We anticipate our cash-to-cash cycle to stabilize between 120 to 125 days. Issues like seasonal demand and our business mix mean fluctuations can occur, but we expect to remain within this range, focusing on steady improvement in operational efficiency.

Question 9: How is our nasal spray portfolio developing?

Answer: We have filed one nasal spray with the USFDA and plan to file two more in the next couple of quarters. Revenue from this category is expected to start realizing in 2027-2028, contingent upon successful approvals.

Question 10: Can you discuss the pricing trends for finished products and raw materials?

Answer: While price erosion is a common aspect of the generics business, we believe COGS improvement can offset this pressure. It's integral to our strategy to manage our supply chain effectively to minimize raw material costs while responding to market conditions.